Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity

Obesity (Silver Spring). 2016 Dec;24(12):2544-2552. doi: 10.1002/oby.21674. Epub 2016 Oct 21.

Abstract

Objective: This study aimed to evaluate whether circulating levels and/or visceral adipose tissue (VAT) expression of recently described adipokines associate with histopathological severity of nonalcoholic fatty liver disease (NAFLD), independent of obesity and insulin resistance.

Methods: Serum levels of adiponectin, omentin, chemerin, monocyte chemoattractant protein-1, and secreted frizzled-related protein 4 were measured using enzyme-linked immunosorbent assay in 81 patients with obesity and NAFLD and 18 lean control subjects. Expression in VAT was measured using real-time PCR and histopathological grading was scored using the NAFLD activity score (NAS).

Results: When NAFLD patients were subdivided into groups with simple steatosis, borderline nonalcoholic steatohepatitis (NASH), and NASH, adiponectin serum levels and omentin expression were lower in NASH versus simple steatosis patients. Serum adiponectin was generally lower with higher histopathological grading. Chemerin VAT expression was negatively associated with NAS (r = -0.331, P = 0.022) and steatosis score (r = -0.335, P = 0.020), independent of age, BMI, and HOMA-IR. In addition, adjusting for chemerin VAT expression in a multivariate model explained part of the association between NAS and HOMA-IR.

Conclusions: These findings suggest that lower VAT expression of chemerin in patients with obesity may be involved in the pathophysiology of hepatic steatosis, potentially by modulating the link between insulin resistance and NAFLD.

MeSH terms

  • Adipokines / blood
  • Biomarkers / blood
  • Chemokines / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Insulin Resistance
  • Intercellular Signaling Peptides and Proteins / blood*
  • Intra-Abdominal Fat / metabolism*
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / metabolism*
  • Obesity / metabolism*
  • Severity of Illness Index

Substances

  • Adipokines
  • Biomarkers
  • Chemokines
  • Intercellular Signaling Peptides and Proteins
  • RARRES2 protein, human